Neuralstem, Inc. is focused on developing and commercializing of treatments for central nervous system disease based on transplanting human neural stem cells and small molecule drugs. The Company has developed and maintain a portfolio of patents and patent applications that form the base of its research and development efforts in the areas of neural stem cell research, small molecule research, and related technologies.
04/10/11Neuralstem shares jump over 13% on new stem cell patent
16/12/10Neuralstem Receives FDA Approval to Start Phase Ia Trial for Depression Drug
14/09/10Study Shows Neuralstem’s Stem Cells May Have Application To Treating Stroke
Recent Sector News
U.S. stocks shook off earlier losses to end markedly higher, as investors focused on a slight bounce in oil prices and better-than-expected jobless claims data. Stocks were mixed earlier in the session as investors weighed economic data against bleak outlooks from several corporations.
The company last month signed an arms-length agreement to acquire and commercialize the rights to a new blood glucose monitoring device for diabetics.
Capricor Therapeutics (NASDAQ:CAPR) had its buy rating and target price of $8 reiterated by analysts at H.C. Wainwright (HCW), who said they have high hopes for the company for a "dynamic" start to 2015.
Ireland-based drug giant Shire (NASDAQ:SHPG) (LON:SHP) has signalled its intention to remain independent with a US$5.2bn deal to buy US speciality drug firm NPS Pharmaceuticals (NASDAQ:NPSP).
The company’s drug delivery system is comprised of a thin film wafer, which is placed on the top floor of the tongue, and is retained at the site of application, rapidly releasing a variety of opioids such as morphine and codeine, as well as narcotics such as marijuana.
Threshold Pharmaceuticals had its “buy” rating and $12 target price reiterated at HC Wainwright, which said the biotechnology company’s investigational anticancer drug TH-302 appears poised to advance in Myeloma. HCW said that at the ongoing ASH meeting in San Francisco last weekend, Threshold presented data from Part C of its Phase 1/2 study of TH-302 in relapsed/refractory multiple myeloma.
Investors interested in Neuralstem recently viewed
- Amphion Innovations (LON: AMP) Amphion builds shareholder value in the medical and technology sectors
- Supreme Pharmaceuticals (CSE: SL) Targeting opportunities in the medical marijuana and obesity sectors
- OncoSil Medical Limited (ASX: OSL) New technology to provide safe radiation treatments
- Medgenics (AMEX , AIM: MDGN) Developing "Biopump" technology for the treatment of chronic diseases
- Horizon Discovery Group (AIM: HZD) .